findmyKOL
Clinical trialNCT01210222CompletedPhase 2Interventional

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer

SponsorGynecologic Oncology GroupEnrollment35Endometrial AdenocarcinomaEndometrial Adenosquamous CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Endometrioid Adenocarcinoma, Variant With Squamous DifferentiationEndometrial Serous AdenocarcinomaEndometrioid Stromal Sarcoma+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Hartford Hospital

    Hartford, Connecticut, United States

  • the Hospital of Central Connecticut

    New Britain, Connecticut, United States

  • Sarasota Memorial Hospital

    Sarasota, Florida, United States

  • Memorial University Medical Center

    Savannah, Georgia, United States

  • Rush University Medical Center

    Chicago, Illinois, United States

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, United States

  • Sudarshan K Sharma Md Limted-Gynecologic Oncology

    Hinsdale, Illinois, United States

  • Memorial Medical Center

    Springfield, Illinois, United States

  • Saint Vincent Hospital and Health Care Center

    Indianapolis, Indiana, United States

  • Mcfarland Clinic Pc-William R Bliss Cancer Center

    Ames, Iowa, United States

  • Iowa Lutheran Hospital

    Des Moines, Iowa, United States

  • Iowa Methodist Medical Center

    Des Moines, Iowa, United States

  • Iowa-Wide Oncology Research Coalition Ncorp

    Des Moines, Iowa, United States

  • Medical Oncology and Hematology Associates-Des Moines

    Des Moines, Iowa, United States

  • Medical Oncology and Hematology Associates-Laurel

    Des Moines, Iowa, United States

  • Mercy Medical Center - Des Moines

    Des Moines, Iowa, United States

  • Maine Medical Center-Bramhall Campus

    Portland, Maine, United States

  • University of Mississippi Medical Center

    Jackson, Mississippi, United States

  • Coxhealth South Hospital

    Springfield, Missouri, United States

  • Nebraska Methodist Hospital

    Omaha, Nebraska, United States

  • Carolinas Medical Center/levine Cancer Institute

    Charlotte, North Carolina, United States

  • Southeast Clinical Oncology Research (scor) Consortium Ncorp

    Winston-Salem, North Carolina, United States

  • Metrohealth Medical Center

    Cleveland, Ohio, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, United States

  • Riverside Methodist Hospital

    Columbus, Ohio, United States

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, United States

  • Oklahoma Cancer Specialists and Research Institute-Tulsa

    Tulsa, Oklahoma, United States

  • Abington Memorial Hospital

    Abington, Pennsylvania, United States

  • Women and Infants Hospital

    Providence, Rhode Island, United States

  • Anmed Health Cancer Center

    Anderson, South Carolina, United States

  • Saint Francis Hospital

    Greenville, South Carolina, United States

  • Huntsman Cancer Institute/university of Utah

    Salt Lake City, Utah, United States

  • Virginia Commonwealth University/massey Cancer Center

    Richmond, Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Trebananib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Jun 2011
Primary completion
16 Jul 2016
Completion
16 Jul 2016
Last update posted
23 Feb 2018
Registered enrollment
35
Registry id
NCT01210222

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.